Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study
This phase 3, prospective, open-label, multicenter, continuation study (NCT01286779) investigated the use of a recombinant factor IX (FIX), nonacog gamma (BAX 326, RIXUBIS ® ) in patients with severe or moderately severe hemophilia B. The study population included 85 patients transitioning from a ph...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publishing
2020-08-01
|
| Seri Bilgileri: | Clinical and Applied Thrombosis/Hemostasis |
| Online Erişim: | https://doi.org/10.1177/1076029620950836 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|